Note: Not all studies are available based on copyrights of the original documents. Please note the PARI Pharma copyright studies are owned by PARI Pharma. Data may not be referenced in any way including print and electronic formats without the prior written consent of PARI Pharma.

[DDL 12-04 022] M. Tservistas, S. Ohl, M. Keller: Influence of inspiratory flow rate on the delivered dose and droplet size distribution of tobramycin delivered by nebuliser systems utilising breath simulation and the Next Generation Impactor (NGI). Drug Delivery to the Lungs XV, Dec. 9 – 10, 2004, London, United Kingdom. Proceedings pp. 220-223 (extended abstract).
[DDL 12-04 021] F.-C. Lintz, M. Keller: A Novel formulation approach for improved nebulised drug delivery of poorly water soluble drugs. Drug Delivery to the Lungs XV, Dec. 9 – 10, 2004, London, United Kingdom. Proceedings pp. 216-219 (extended abstract).
[AAPS 11-04 020] F.-C. Lintz, S. von Opolski, M. Hug, A. Bucholski, M. Keller: Development of Aqueous Solubilized Corticoid Formulations for Nebulization with a Vibrating Membrane Nebulizer. AAPS Annual Meeting, Baltimore, USA, November 7-11, 2004 (poster).
[NACF 10-04 019] M. Tservistas, R. Lichtinghagen, N. Boden, M. Knoch, M. Keller: Increased Efficiency of Pulmozyme® Delivered by the Novel eFlow® Electronic Inhaler. Eighteenth Annual North American Cystic Fibrosis Conference, October 14-17, 2004, St. Louis, USA.
[NACF 10-04 018] M. Keller, A. Balcke, A. Bucholski, M. Hug, R. Waldner: Performance Characteristics of Colistimethate Sodium Solution (Colistin) Nebulized by a Novel Electronic Inhaler (eFlow®). Eighteenth Annual North American Cystic Fibrosis Conference, October 14-17, 2004, St. Louis, USA (oral presentation, extended version).
[NACF 10-04 017] M. Keller, A. Balcke, A. Bucholski, M. Hug, R. Waldner: Performance Characteristics of Colistimethate Sodium Solution (Colistin) Nebulized by a Novel Electronic Inhaler (eFlow®). Eighteenth Annual North American Cystic Fibrosis Conference, October 14-17, 2004, St. Louis, USA (poster presentation, short version).
[MF 10-04 016] R. Stangl: Continuous Mode or Breath Trigger System. Aqueous Droplet Inhalers: Conference organised by Management Forum, London, October 11 – 12, 2004 (oral presentation).
[MF 10-04 015] M. Keller: Setting the Right Targets and Specifications for a Successful Product Development of Aqueous Droplet Inhalers. Aqueous Droplet Inhalers: Conference organised by Management Forum, London, October 11 – 12, 2004 (oral presentation).
[ERS 09-04 014] M. Keller, J. Jauernig, S. Ohl, M. Knoch: Prediction of the lung dose in young children by cascade impaction methods alternatively to the SAINT model. European Respiratory Society Annual Congress, Glasgow, Scotland, Sept. 4 – 8, 2004 (poster). European Respiratory Journal 24; S48, 2004, pp. 621s-622s (abstract).
[ECFC 06-04 013] F. Friedrich, M. Keller, H. Döhmen, C. Pfannenstiel, R. Ledermüller: Comparison of tobramycin serum plasma levels in 5 CF patients after inhalation via a PARI LC PLUS® nebuliser and via eFlow®, a novel electronic inhaler. 27th European Cystic Fibrosis Conference, Birmingham, United Kingdom, June 13 – 17, 2004 (poster). Journal of Cystic Fibrosis, vol 3, suppl 1, S64; 2004
[ECFC 06-04 012] A. Balcke, A. Bucholski, R. Waldner, M. Knoch, M. Keller: Performance characteristics of colistinmethate sodium solution (Colistin) nebulised by jet nebulisers compared to the novel electronic inhaler (eFlow®). 27th European Cystic Fibrosis Conference, Birmingham, United Kingdom, June 13 – 17, 2004 (poster). Journal of cystic fibrosis, vol 3, suppl 1, S63, 2004
[ECFC 06-04 011] M. Tservistas, R. Lichtinghagen, N. Boden, A. Schmitt, S. Seemann, M. Keller: Assessment of enzyme activity following nebulization with the eFlow™ electronic nebulizer. 27th European Cystic Fibrosis Conference, Birmingham, United Kingdom, June 13 – 17, 2004 (oral presentation).
[ATS 05-04 010] S. Seemann, R. Waldner, M. Knoch, M. Keller: A New Electronic Inhaler (eFlow®) to Improve Delivery of Inhaled Medications on CF Patients. ATS, Orlando, USA, May 21-26, 2004 (poster).
[ATS 05-04 009] J. Jauernig, S. Ohl, M. Keller: A Novel Budesonide Formulation (BUDeFlow™) to Improve Asthma Treatment in Babies Using a New Electronic Inhaler (eFlow® baby). ATS, Orlando, USA, May 21-26, 2004 (poster).
[RDD 04-04 008] M. Keller, J. Jauernig, K. Schueepp, R. Stangl, S. Ohl, C. Roller, S. Devadason, J. Wildhaber: Using Infant Deposition Models to Improve Inhaler System Design. Respiratory Drug Delivery IX, Palm Desert, California, USA, April 25 – 29, 2004 (oral presentation). Proceedings pp. 221-231.
[RDD 04-04 007] A. Boehm, M. Luber, H. Mentzel, M. Knoch: Investigating Drug Delivery to the Sinuses – An In-Vitro Deposition Study Using a Nasal Cast Model. Respiratory Drug Delivery IX, Palm Desert, California, USA, April 25 – 29, 2004 (poster presentation). Proceedings pp. 601 – 604.
[RDD 04-04 006] M. Borgschulte, M. Germer, M. Hug, M. Keller, M. Knoch, R. Stangl: Means to Optimize Drug Delivery from a Novel Electronic Inhaler (eFlow®). Respiratory Drug Delivery IX, Palm Desert, California, USA, April 25 – 29, 2004 (poster presentation). Proceedings pp. 605 – 608.
[RDD 04-04 005] J. Jauernig, S. Ohl, M. Knoch, M. Keller: Effects of the Test Set-Up, Formulation, and Nebulizer Type on Aerodynamic Droplet Characteristics. Respiratory Drug Delivery IX, Palm Desert, California, USA, April 25 – 29, 2004 (poster presentation). Proceedings pp. 609 – 612.
[RDD 04-04 004] M. Tservistas, F.-C. Lintz, M. Keller: Impact of the Nebulization Principle on the Biological Activity of Labile Formulations Containing Liposomes, Peptides, Proteins. Respiratory Drug Delivery IX, Palm Desert, California, USA, April 25 – 29, 2004 (poster presentation). Proceedings pp. 613 – 615. K. G. Schüepp, D. Straub, A. Möller, J. H. Wildhaber: Deposition of Aerosols in Infants and Children. Journal of Aerosol Medicine, vol. 17, no. 2, 2004, pp. 153-156.
[GPP 03-04 003] M. Tservistas: Aktivität von Dornase alfa nach der Verneblung mit eFlow®. Jahrestagung der Gesellschaft für Pädiatrische Pneumologie, Hamburg, Germany, March 25-27, 2004 (oral presentation.
[DGP 03-04 002] M. Keller, A. Balcke, P. Stempfle, R. Ledermüller,M. Knoch: Einfluss des Verneblertyps und der Medikamenten-Formulierung auf die inhalativ in-vitro verfügbare Tobramycin-Dosis. 45. KONGRESS DER DEUTSCHEN GESELLSCHAFT FÜR PNEUMOLOGIE, Frankfurt, Germany, March 10-13, 2004.
[DGP 03-04 001] M. Tservistas, U. Schuschnig, R. Ledermüller, M. Knoch, M. Keller: Unterschiede in der Vernebelungseffizienz von Pulmicort in Abhängigkeit vom Verneblertyp. 45. KONGRESS DER DEUTSCHEN GESELLSCHAFT FÜR PNEUMOLOGIE, Frankfurt, Germany, March 10-13, 2004.